These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 19549613)

  • 1. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
    Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
    Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
    Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
    Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
    Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
    J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.
    Bogdanos DP; Rigopoulou EI; Smyk DS; Roggenbuck D; Reinhold D; Forbes A; Laass MW; Conrad K
    Autoimmun Rev; 2011 Dec; 11(2):143-8. PubMed ID: 21983481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
    Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
    Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease.
    Liaskos C; Spyrou V; Roggenbuck D; Athanasiou LV; Orfanidou T; Mavropoulos A; Reinhold D; Rigopoulou EI; Amiridis GS; Billinis C; Bogdanos DP
    Autoimmunity; 2013 Sep; 46(6):388-94. PubMed ID: 23638886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
    Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
    BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
    Pavlidis P; Shums Z; Koutsoumpas AL; Milo J; Papp M; Umemura T; Lakatos PL; Smyk DS; Bogdanos DP; Forbes A; Norman GL
    Clin Chim Acta; 2015 Feb; 441():176-81. PubMed ID: 25512163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein 2 antibodies in Crohn's disease.
    Roggenbuck D; Reinhold D; Werner L; Schierack P; Bogdanos DP; Conrad K
    Adv Clin Chem; 2013; 60():187-208. PubMed ID: 23724745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.
    Pavlidis P; Romanidou O; Roggenbuck D; Mytilinaiou MG; Al-Sulttan F; Liaskos C; Smyk DS; Koutsoumpas AL; Rigopoulou EI; Conrad K; Forbes A; Bogdanos DP
    Clin Dev Immunol; 2012; 2012():640835. PubMed ID: 23118780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
    Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
    Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Kossa K; Coulthart A; Ives CT; Pusey CD; Hodgson HJ
    Eur J Gastroenterol Hepatol; 1995 Aug; 7(8):783-9. PubMed ID: 7496870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease?
    Castellino F; Rosina F; Bansi DS; Bauducci M; Touscoz GA; Giorda L; Borghesio E; Bessone MP; Astegiano M; Musso A
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):859-64. PubMed ID: 8574718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.
    Farkona S; Soosaipillai A; Filippou P; Liaskos C; Bogdanos DP; Diamandis EP; Blasutig IM
    Clin Chem Lab Med; 2017 Aug; 55(10):1574-1581. PubMed ID: 28343172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles IgM immunoreactivity in patients with inflammatory bowel disease.
    Balzola FA; Khan K; Pera A; Bonino F; Pounder RE; Wakefield AJ
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):378-82. PubMed ID: 9789132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases.
    Colombel JF; Reumaux D; Duthilleul P; Noël LH; Gower-Rousseau C; Paris JC; Cortot A
    Gastroenterol Clin Biol; 1992; 16(8-9):656-60. PubMed ID: 1426820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Autoantibodies against the exocrine pancreas and against intestinal goblet cells in the diagnosis of Crohn's disease and ulcerative colitis].
    Stöcker W; Otte M; Ulrich S; Normann D; Stöcker K; Jantschek G
    Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1963-9. PubMed ID: 6150841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
    Cummings D; Cruise M; Lopez R; Roggenbuck D; Jairath V; Wang Y; Shen B; Rieder F
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1251-1259. PubMed ID: 30411391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn's disease have autoantibodies to type VII collagen.
    Chen M; O'Toole EA; Sanghavi J; Mahmud N; Kelleher D; Weir D; Fairley JA; Woodley DT
    J Invest Dermatol; 2002 Jun; 118(6):1059-64. PubMed ID: 12060403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.